BiotechTube

pegfilgrastim

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neutropenia

Conditions

Neutropenia

Trial Timeline

Mar 1, 2006 → Mar 1, 2008

NCT ID
NCT00364468

About pegfilgrastim

pegfilgrastim is a phase 2 stage product being developed by Kyowa Kirin for Neutropenia. The current trial status is completed. This product is registered under clinical trial identifier NCT00364468. Target conditions include Neutropenia.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT03993639Phase 2Completed
NCT00364468Phase 2Completed

Competing Products

20 competing products in Neutropenia

See all competitors
ProductCompanyStageHype Score
MicafunginAstellas PharmaApproved
85
HHPG-19K InjectionJiangsu Hengrui MedicinePhase 3
77
caspofungin acetate + Comparator: AmBisomeMerckPhase 2
52
Imipenem + ImipenemMerckApproved
85
Posaconazole IV solution + Posaconazole powder for oral suspensionMerckPhase 1
33
Ceftolozane-Tazobactam + MeropenemMerckApproved
85
Ceftolozane-tazobactam IVMerckApproved
85
Daptomycin + DaptomycinMerckPhase 3
77
pegfilgrastimAmgenPhase 3
76
Neulasta (pegfilgrastim)AmgenApproved
84
Liposomal amphotericin B (AmBisome®) + Liposomal amphotericin B (AmBisome®)Gilead SciencesApproved
84
Filgrastim Hospira (US) + US-approved Neupogen®PfizerPhase 1
32
HSP-130 + US-approved Neulasta + EU-approved NeulastaPfizerPhase 1
32
linezolid + vancomycinPfizerPhase 3
76
AnidulafunginPfizerPhase 1/2
40
Nivestim®PfizerPre-clinical
22
Antibacterial agent for the treatment of febrile neutropeniaPfizerPre-clinical
22
VoriconazolePfizerPhase 1/2
40
Filgrastim Hospira (US) + U.S.-approved Neupogen®PfizerPhase 1
32
ciprofloxacin + cefepimeBayerPhase 3
74

Other Products from Kyowa Kirin

KRN23Approved
85
Istradefylline PillApproved
85
MogamulizumabApproved
85
KRN23Approved
85
KHK4827-Active + KHK4827-PlaceboApproved
85